Rapid Diagnostic Testing for Response to the Monkeypox Outbreak

Laboratory Response Network, United States, May 17-June 30, 2022

Tricia A. Aden; Patricia Blevins, MPH; Shannon Whitman York, PhD; Stacy Rager; Devika Balachandran, MPA, MBA; Christina L. Hutson, PhD; David Lowe, PhD; Chris N. Mangal MPH; Tyler Wolford, MS; Audrey Matheny; Whitni Davidson, MPH; Kimberly Wilkins; Rachael Cook, PharmD; Rebecca M. Roulo, MS; Michael K. White; LaShondra Berman, MSc; Janna' Murray, MPH; John Laurance; Drew Francis; Nicole M. Green, PhD; Ricardo A. Berumen III; Anthony Gonzalez, PhD; Stacy Evans; Meghan Hudziec; Diane Noel; Michael Adjei, PhD; Gregory Hovan, MBA; Phil Lee, MSc; Lisa Tate; Remedios B. Gose, MSPH; Robert Voermans; Jennifer Crew, PhD; Phillip R. Adam, PhD; Danielle Haydel; Salimatu Lukula; Nick Matluk, PhD; Sandip Shah, PhD; Joshua Featherston; Daphne Ware, PhD; Denise Pettit, PhD; Emily McCutchen, MS; Edward Acheampong, PhD; Erin Buttery, MBA; Andrew Gorzalski, PhD; Michael Perry, MS, MSEd; Randal Fowler, PhD; Robert B. Lee, PhD; Robert Nickla; Richard Huard, PhD; Amanda Moore; Katie Jones; Renee Johnson; Erin Swaney; Juan Jaramillo; Cynthia Reinoso Webb, PhD; Brandon Guin; Janine Yost; Annette Atkinson, MS; Latoya Griffin-Thomas, PhD; Jessica Chenette; Jessica Gant, MS; Alana Sterkel, PhD; Harjinder K. Ghuman, MS; James Lute, PhD; Sandra C. Smole, PhD; Vaneet Arora, MD; Courtney K. Demontigny, MS; Meilan Bielby, PhD; Evelyn Geeter; Kimberly A. M. Newman, MS; Mark Glazier; Whitney Lutkemeier, MS; Megan Nelson, MS; Raymond Martinez; Jasmine Chaitram, MPH; Margaret A. Honein, PhD; Julie M. Villanueva, PhD

Disclosures

Morbidity and Mortality Weekly Report. 2022;71(28):904-907. 

In This Article

Abstract and Introduction

Introduction

As part of public health preparedness for infectious disease threats, CDC collaborates with other U.S. public health officials to ensure that the Laboratory Response Network (LRN) has diagnostic tools to detect Orthopoxviruses, the genus that includes Variola virus, the causative agent of smallpox. LRN is a network of state and local public health, federal, U.S. Department of Defense (DOD), veterinary, food, and environmental testing laboratories. CDC developed, and the Food and Drug Administration (FDA) granted 510(k) clearance* for the Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set (non-variola Orthopoxvirus [NVO] assay), a polymerase chain reaction (PCR) diagnostic test to detect NVO. On May 17, 2022, CDC was contacted by the Massachusetts Department of Public Health (DPH) regarding a suspected case of monkeypox, a disease caused by the Orthopoxvirus Monkeypox virus. Specimens were collected and tested by the Massachusetts DPH public health laboratory with LRN testing capability using the NVO assay. Nationwide, 68 LRN laboratories had capacity to test approximately 8,000 NVO tests per week during June. During May 17–June 30, LRN laboratories tested 2,009 specimens from suspected monkeypox cases. Among those, 730 (36.3%) specimens from 395 patients were positive for NVO. NVO-positive specimens from 159 persons were confirmed by CDC to be monkeypox; final characterization is pending for 236. Prompt identification of persons with infection allowed rapid response to the outbreak, including isolation and treatment of patients, administration of vaccines, and other public health action. To further facilitate access to testing and increase convenience for providers and patients by using existing provider-laboratory relationships, CDC and LRN are supporting five large commercial laboratories with a national footprint (Aegis Science, LabCorp, Mayo Clinic Laboratories, Quest Diagnostics, and Sonic Healthcare) to establish NVO testing capacity of 10,000 specimens per week per laboratory. On July 6, 2022, the first commercial laboratory began accepting specimens for NVO testing based on clinician orders.

LRN was established in 1999 as a partnership among CDC, the Federal Bureau of Investigation, and the Association of Public Health Laboratories, with the goal of ensuring a laboratory infrastructure across the United States that can respond quickly and effectively to biothreats, chemical threats, and emerging infectious diseases.[1] LRN provides the framework to rapidly distribute laboratory diagnostic tests, standardized reagents, and standard operating procedures, and to train laboratory personnel, report laboratory test results, and provide critical communication during routine and emergency responses. LRN includes approximately 110 U.S. laboratories, primarily state and local public health and DOD laboratories, as well as veterinary, food, and environmental testing laboratories. LRN laboratories are required to participate in proficiency testing exercises to ensure competency for laboratory test methods distributed to the network.

To effectively respond to a potential Orthopoxvirus outbreak, CDC subject matter experts worked with LRN to design, develop, and validate an assay to detect NVOs, such as Vaccinia, Cowpox, Monkeypox, and Ectromelia viruses, if suspected cases were identified. The NVO assay first received 510(k) clearance by FDA in 2005 and was cleared again in 2018 to update the labeling and use of reagents. The NVO assay does not differentiate Monkeypox virus from other Orthopoxviruses. NVOs are not endemic in the United States; however, the NVO assay has been used to detect cases of Vaccinia virus infection associated with vaccination and two imported cases of monkeypox from travelers in 2021.[2]

CDC recommends that for each patient, clinicians collect two specimens, each from multiple lesions, preferably from different locations on the body and from lesions with differing appearances.[3] The CDC Monkeypox virus testing algorithm includes NVO testing, and if results are positive for Orthopoxvirus, further characterization testing at CDC.[4] A subset of specimens was characterized at CDC by a Monkeypox virus specific real-time PCR assay and genetic sequencing.§ The median LRN laboratory testing turnaround time was calculated from the time of specimen receipt by LRN testing laboratories to arrival of NVO test results at CDC. Testing capacity was estimated and reported by LRN laboratories. This report describes NVO testing by LRN during May 17–June 30, 2022. This investigation was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.

As of June 10, 68 U.S. LRN laboratories, located in 47 states and the District of Columbia, had implemented the NVO assay updated in 2018 and tested specimens from patients with probable monkeypox cases. These laboratories reported an estimated total testing capacity of 8,000 specimens per week. LRN laboratories reported that capacity of NVO testing laboratories was limited by reagent availability and the requirement for manual DNA extraction. To increase testing throughput and build capacity, the NVO assay was rapidly updated to include additional controls, automated extraction, and real-time PCR instrumentation in collaboration with FDA; the updated assay received 510(k) clearance on June 10, 2022. As of June 30, 2022, 78 LRN laboratories had implemented the NVO assay and have reported a total testing capacity of 24,000 specimens per week with implementation of substantial operational changes such as adding extra shifts, reassigning personnel, and shifting testing priorities based on laboratory emergency response plans.

During May 17–June 30, a total of 2,009 specimens were tested in LRN laboratories (Table); 730 (36.3%) specimens from 395 persons across 31 jurisdictions (including 29 states, District of Columbia, and Puerto Rico) were confirmed positive for Orthopoxvirus using the NVO assay. One positive specimen from each patient (159) was sent to CDC and further characterized as Monkeypox virus belonging to the West African clade; as of June 30, 236 confirmed Orthopoxvirus cases were pending characterization. The median LRN laboratory testing turnaround time was 30.7 hours for all results (Table).

Although LRN laboratories provide initial recognition and detection of emerging infectious diseases, rapid expansion of nationwide testing capacity was indicated for this outbreak. Therefore, CDC obtained 510(k) clearance from FDA on June 23 to enable CDC to provide the NVO assay to five large commercial laboratories under a licensing agreement that included CDC training and test verification before the start of testing. This expansion of testing provides additional test capacity and electronic laboratory reporting to public health authorities, makes testing more accessible, and streamlines diagnostic testing for multiple, possible infections. When fully operational, these five national commercial laboratories are anticipated to increase weekly testing capacity nationwide by approximately 10,000 specimens per laboratory.

*https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances
https://emergency.cdc.gov/lrn/usmap.asp
§ https://www.biorxiv.org/content/10.1101/2022.06.10.495526v1
45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

processing....